CTIS2023-505576-29-00招募中1 期
LB101-101
Centessa Pharmaceuticals UK Limited0 个研究点目标入组 180 人开始时间: 2023年7月24日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung CancerOncologyMedDRA version: 21.1Level: PTClassification code: 10029517Term: Non-small cell lung cancer stage I Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029516Term: Non-small cell lung cancer stage 0 Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029518Term: Non-small cell lung cancer stage II Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non-small cell lung cancer stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029520Term: Non-small cell lung cancer stage IIIA Class: 100000004864CTIS2023-506539-14-00Systimmune Inc.144
招募中
1 期
First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphomaymphoma, Solid tumorMedDRA version: 20.0Level: HLGTClassification code: 10025323Term: Lymphomas NEC Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2023-509532-25-00eukos Biotech S.L.42
招募中
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCERCTIS2023-508058-24-01ovImmune S.A.12
进行中（未招募）
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCEROCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERCTIS2023-508058-24-00ovImmune S.A.12
进行中（未招募）
1 期
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy SubjectsAdvanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation., Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine in adults., Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10014743Term: Endometrial carcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10007476Term: Carcinoma thyroid Class: 10029104CTIS2022-501327-25-00Bluepharma Industria Farmaceutica S.A.36